Difficulty: Medium
Average Score: 93%
Practice
For majority of patients of parkinsonism, the standard drug therapy is
Correct answer
B
Rationale
In the treatment of Parkinsonism, the standard drug therapy for the majority of patients is Levodopa combined with Carbidopa (Option B). Levodopa is the most effective medication for managing the symptoms of Parkinson's disease as it is a precursor to dopamine, a neurotransmitter that is deficient in Parkinson's patients. Carbidopa is often combined with Levodopa to prevent the peripheral breakdown of Levodopa before it reaches the brain, thus increasing the amount of Levodopa available to cross the blood-brain barrier and be converted to dopamine in the brain.
Option A (Levodopa alone) is less effective because Levodopa alone is rapidly metabolized in the periphery, leading to limited amounts of Levodopa reaching the brain to exert its therapeutic effects. Option C (Levodopa + Trihexyphenidyl) is incorrect as Trihexyphenidyl is an anticholinergic medication used for managing tremors and muscle stiffness in Parkinson's disease but is not a standard first-line therapy. Option D (Bromocriptine) is a dopamine agonist used in Parkinson's disease, but it is not typically considered the standard initial therapy for most patients.
Understanding the rationale behind choosing the correct medication for Parkinsonism is crucial for healthcare professionals involved in the management of neurological conditions. By selecting the appropriate drug therapy based on the underlying pathophysiology and the patient's symptoms, healthcare providers can optimize treatment outcomes and improve the quality of life for patients with Parkinson's disease.
Option A (Levodopa alone) is less effective because Levodopa alone is rapidly metabolized in the periphery, leading to limited amounts of Levodopa reaching the brain to exert its therapeutic effects. Option C (Levodopa + Trihexyphenidyl) is incorrect as Trihexyphenidyl is an anticholinergic medication used for managing tremors and muscle stiffness in Parkinson's disease but is not a standard first-line therapy. Option D (Bromocriptine) is a dopamine agonist used in Parkinson's disease, but it is not typically considered the standard initial therapy for most patients.
Understanding the rationale behind choosing the correct medication for Parkinsonism is crucial for healthcare professionals involved in the management of neurological conditions. By selecting the appropriate drug therapy based on the underlying pathophysiology and the patient's symptoms, healthcare providers can optimize treatment outcomes and improve the quality of life for patients with Parkinson's disease.